Taking into account the most recent developments, particularly the KarXT ( Cobenfy ) FDA approval , which is poised to be a game changer in the treatment of Schizophrenia, together with the significant advances in the oncology portfolioOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising m ...